Chi-sheng Shia
TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate.
Journal: Molecular cancer therapeutics
Published: December 14, 2024
OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.
Journal: Molecular cancer therapeutics
Published: July 17, 2024
Erratum: A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Journal: American journal of cancer research
Published: October 12, 2023
Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors.
Journal: British journal of cancer
Published: September 30, 2022
A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Journal: American journal of cancer research
Published: February 17, 2021
Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate.
Journal: Molecular cancer therapeutics
Published: September 08, 2020
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 14, 2019
Increased Systemic Exposure of Methotrexate by a Polyphenol-Rich Herb via Modulation on Efflux Transporters Multidrug Resistance-Associated Protein 2 and Breast Cancer Resistance Protein.
Journal: Journal of pharmaceutical sciences
Published: September 06, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026